February 7, 2019
Authored and Edited by Ryan P. O'Quinn, Ph.D.; Shana K. Cyr, Ph.D.
On January 30, 2019, FDA Commissioner Scott Gottlieb issued a statement on FDA’s efforts to enhance the utility of the Orange Book to foster drug competition. Noting the benefits of a modern, up-to-date Orange Book, the Commissioner announced several steps that FDA is taking.
First, FDA issued draft guidance in January 2019, entitled “Marketing Status Notifications Under Section 506I of the Federal Food, Drug, and Cosmetic Act; Content and Format.” This guidance identified the required content for marketing status notifications, the recommended format for submitting the notifications to FDA, and the required timelines for submission.
Second, FDA will issue guidance for industry regarding how it evaluates therapeutic equivalence and assigns therapeutic equivalence codes. According to the Commissioner, FDA believes this guidance will be particularly beneficial for those seeking to develop generic products for harder-to-copy complex drugs.
Third, FDA will issue guidance to assist drug product applicants and approved application holders in using the Orange Book, including answers to commonly asked questions.
Fourth, FDA plans to solicit public comment on Orange Book use and potential enhancements. According to the Commissioner, this will include reexamining what pharmaceutical patents should be listed in the Orange Book and whether it should include, for example, patents associated with the digital application for products approved in conjunction with a digital application.
Readers are encouraged to read the Commissioner’s statement, also available on FDA’s website.
Food and Drug Administration (FDA), drugs, combination product, 505(b)(2) application, generic drug, Hatch-Waxman Act, new drug application (NDA), Orange Book, 2019 Top Insights
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
May 9, 2024
Webinar
INCONTESTABLE® Blog
April 19, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.